Abstract:Neurodegenerative parkinsonian syndromes comprise a number of disorders that are characterized by similar clinical features but are separated on the basis of different pathologies, i.e., aggregates of α-synuclein or tau protein. Due to the overlap of signs and symptoms a precise differentiation is often difficult, especially early in the disease course. Enormous efforts have been taken to develop tau-selective PET imaging agents, but strong off-target binding to monoamine oxidase B (MAO-B) has been observed across first generation ligands. Nonetheless, astrogliosis-related MAO-B elevation is a common histopathological known feature of all parkinsonian syndromes and might be itself an interesting imaging target. Therefore, this study aimed to investigate the performance of [18F]-THK5351, a combined MAO-B and tau tracer for differential diagnosis of parkinsonian syndromes. [18F]-THK5351 PET was performed in 34 patients: six with Parkinson's disease (PD), nine with multiple system atrophy with predominant parkinsonism (MSA-P), six with MSA with predominant cerebellar ataxia (MSA-C), and 13 with progressive supranuclear palsy (PSP) Richardson's syndrome. Volume-of-interest-based quantification of standardized-uptake-values was conducted in different parkinsonian syndrome-related target regions. PET results were subjected to multinomial logistic regression to create a prediction model discriminating among groups. Furthermore, we correlated tracer uptake with clinical findings. Elevated [18F]-THK5351 uptake in midbrain and diencephalon differentiated PSP patients from PD and MSA-C. MSA-C patients were distinguishable by high tracer uptake in the pons and cerebellar deep white matter when compared to PSP and PD patients, whereas MSA-P patients tended to show higher tracer uptake in the lentiform nucleus. A multinomial logistic regression classified 33/34 patients into the correct clinical diagnosis group. Tracer uptake in the pons, cerebellar deep white matter, and striatum was closely associated with the presence of cerebellar and parkinsonian symptoms of MSA patients. The current study demonstrates that combined MAO-B and tau binding of THK5351 facilitates differential diagnosis of parkinsonian syndromes. Furthermore, our data indicate a correlation of MSA phenotype with [18F]-THK5351 uptake in certain brain regions, illustrating their relevance for the emergence of clinical symptoms and underlining the potential of THK5351 PET as a biomarker that correlates with pathological changes as well as with disease stage.

Clinical Application of 18 F-THK5351 PET to Image Ongoing Astrogliosis in MSA-P and MSA-C

Clinical Application of 18F-THK5351 PET to Image Ongoing Astrogliosis in MSA-P and MSA-C

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes

18F-THK5351 PET Is Superior to Conventional MRI in Identifying Inflammatory Lesions by Imaging Astrogliosis in 2 Cases of Neurosyphilis

18 F-THK5351 PET Is Superior to Conventional MRI in Identifying Inflammatory Lesions by Imaging Astrogliosis in 2 Cases of Neurosyphilis

Increased 18F-THK5351 Uptake at Bilateral Primary Motor Cortex in Patients with Progressive Pseudobulbar Palsy

123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

18F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype

Reactive Astrocytes Promote Axonal Remodeling of the Corticospinal Tract During Neuronal Recovery Revealed by 18F-THK5351 PET

Dopamine Transporter PET Imaging in Patients with Parkinson Variant of Multiple System Atrophy and Parkinson''s Disease

Increased Uptake of 18F-THK5351 in Isocitrate Dehydrogenase-Wildtype Glioblastoma But Not in Meningioma

18F-Florbetaben PET/CT for the Diagnosis and Subtyping of Cardiac Amyloidosis: A Case Series and Review of the Literature

Clinical Utility of 18 F‐APN ‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

In Vivo Reactive Astrocyte Imaging in Patients With Schizophrenia Using [ 18 F]THK5351

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

In Vivo Reactive Astrocyte Imaging Using [18F]SMBT-1 in Tauopathy and Familial Alzheimer’s Disease Mouse Models - a Multitracer Study

Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism

Application of 18F-AV45 PET Imaging in Subtle Cognitive Decline and Mild Cognitive Impairment Patients